PureTech Health plc (NASDAQ: PRTC) announced its intention to voluntarily delist its American Depositary Shares from NASDAQ and concentrate trading on the London Stock Exchange, according to a company statement.

The biotherapeutics company notified NASDAQ of its plan to delist the ADSs, with each representing rights to ten ordinary shares. PureTech's ordinary shares will remain listed on the London Stock Exchange as the primary trading venue.

The company's board determined that maintaining a dual listing is no longer necessary following a review of listing structure and shareholder trading patterns. The majority of trading volume, liquidity, and price discovery for PureTech's shares occurs on the LSE, with most of the investor base and governance framework centered in the United Kingdom.

PureTech expects to file a Form 25 with the U.S. Securities and Exchange Commission on or about May 11, 2026, relating to the delisting. The delisting is expected to become effective ten days later, with the last day of NASDAQ trading anticipated on or about May 20, 2026.

Following the delisting, the company's ADSs are expected to be quoted and traded on the over-the-counter market via a sponsored Level 1 ADR program until PureTech considers terminating its American Depositary Receipt program. No action is required from ADS holders at this time.

"We have determined that concentrating our listing on the London Stock Exchange is the most effective way to support our shareholders and execute our strategy," said Robert Lyne, Chief Executive Officer.

The company plans to file a Form 15F with the SEC to deregister its securities and terminate reporting obligations under the Securities Exchange Act of 1934. Upon filing, reporting obligations with the SEC will be suspended immediately, with termination expected within 90 days if there are no SEC objections.